CymaBay Therapeutics
CBAY
$32.48
Share price
0.00%
Change (1 day)
221.27%
Change (1 year)
Categories
P/S ratio for CymaBay Therapeutics (CBAY)
P/S ratio as of May 2024 (TTM): 120
According to CymaBay Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 119.983. At the end of 2023 the company had a P/S ratio of 86.2.
P/S ratio history for CymaBay Therapeutics from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 86.2 | |
| 2022 | N/A | |
| 2021 | N/A | |
| 2020 | N/A | |
| 2019 | N/A | |
| 2018 | N/A | -100% |
| 2017 | 40.4 | |
| 2016 | N/A | |
| 2015 | N/A | |
| 2014 | N/A |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.68 | -97.77% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 1.95 | -98.38% | 🇺🇸 USA |
 Xencor XNCR | 8.65 | -92.79% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | 2.75 | -97.71% | 🇺🇸 USA |